小剂量沙利度胺治疗骨髓增生异常综合征21例疗效观察  

Efficacy of low-dose thalidomide on myelodysplastic syndrome:Report of 21 cases

作　　者：殷献录[1] 李静[1] 

机构地区：[1]安徽省蚌埠市第三人民医院血液科,233000

出　　处：《蚌埠医学院学报》2008年第2期176-177,共2页Journal of Bengbu Medical College

摘　　要：目的:观察小剂量沙利度胺治疗骨髓增生异常综合征(MDS)的疗效与不良反应。方法:沙利度胺联合雄激素及维甲酸治疗MDS21例,其中低危患者(RA/RARS)12例,高危患者(RAEB)9例。结果:总有效率47.6%;12例低危患者中6例获得血液学进步(HI),有效率50.0%;9例高危患者中1例完全缓解(CR),1例部分缓解(PR),2例血液学进步,两组有效率差异无统计学意义(P>0.05)。所有接受沙利度胺治疗的21例患者,8例获血液学进步,其中HI-E6例,HI-P4例,HI-N3例。无明显不良反应。结论:小剂量沙利度胺治疗骨MDS疗效肯定,尤其对那些依赖红细胞输注的MDS的患者疗效明显,副作用小,可作为治疗MDS首选的单一或联合用药。Objective： To observe the effect and side-effect of low-dose thalidomide in treatment for myelodysplastic syndromes （MDS）. Methods：Twelve cases of low-risk MDS （RA/RARS） and 9 eases of high-risk MDS （RAEB） were treated by combined therapy of thalidomide, androgen and retinoie acid. Results： The total response rate was 47. 6%. In the low-rlsk MDS group, hematological improvement （HI） was observed in 6 cases,with an effective rate of 50.0% ;in the high-risk MDS group, complete remission （CR） was achieved in 1 case,partial remission （PR） in 1 case and hematological improvement（HI） in 4 cases. There was no significant difference between the two groups （P 〉 0.05 ）. Eight of the 21 patients receiving thalidomide achieved HI （6 HI-E ,4 HI-P and 3 HI-N ）, no side effects were found. Conclusions：Low-dose thalidomide has positive effect on MDS with little side effect, and the effect is more obvious on the patients who rely on red blood cell transfusion. Thalidomide is the first choice of single or combination drug for patients with MDS.

关 键 词：骨髓增生异常综合征 肿瘤/药物疗法 沙利度胺 

分 类 号：R551.3[医药卫生—血液循环系统疾病] R730.53[医药卫生—内科学]